Your browser is no longer supported. Please, upgrade your browser.
AMGN [NASD]
Amgen Inc.
IndexDJIA S&P500 P/E23.18 EPS (ttm)9.71 Insider Own0.21% Shs Outstand567.00M Perf Week-3.76%
Market Cap127.41B Forward P/E12.55 EPS next Y17.93 Insider Trans0.00% Shs Float562.18M Perf Month0.56%
Income5.61B PEG4.19 EPS next Q4.12 Inst Own77.20% Short Float2.15% Perf Quarter8.39%
Sales25.77B P/S4.94 EPS this Y-4.40% Inst Trans0.12% Short Ratio4.22 Perf Half Y-8.03%
Book/sh14.49 P/B15.53 EPS next Y6.30% ROA9.00% Target Price240.42 Perf Year-12.98%
Cash/sh22.82 P/C9.86 EPS next 5Y5.53% ROE63.70% 52W Range198.64 - 276.69 Perf YTD0.03%
Dividend7.76 P/FCF32.80 EPS past 5Y6.30% ROI19.50% 52W High-18.67% Beta0.61
Dividend %3.45% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin75.40% 52W Low13.29% ATR4.69
Employees24300 Current Ratio1.60 Sales Q/Q4.40% Oper. Margin28.50% RSI (14)48.85 Volatility2.41% 1.87%
OptionableYes Debt/Eq4.57 EPS Q/Q-3.70% Profit Margin21.80% Rel Volume0.94 Prev Close226.08
ShortableYes LT Debt/Eq4.05 EarningsFeb 07 AMC Payout70.40% Avg Volume2.86M Price225.04
Recom2.50 SMA20-1.53% SMA503.47% SMA200-1.48% Volume2,686,088 Change-0.46%
Jan-05-22Downgrade BofA Securities Buy → Neutral $285 → $255
Dec-09-21Resumed Wells Fargo Equal Weight $210
Dec-06-21Initiated Goldman Buy $258
Nov-19-21Initiated BMO Capital Markets Market Perform $228
Sep-23-21Downgrade Daiwa Securities Outperform → Neutral $220
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $280 → $251
Dec-29-20Initiated Daiwa Securities Buy $300
Oct-28-20Initiated UBS Neutral $232
Oct-26-20Upgrade Raymond James Mkt Perform → Outperform $255
Oct-12-20Upgrade Truist Hold → Buy
Oct-09-20Downgrade Truist Buy → Hold $251
Oct-09-20Downgrade Bernstein Outperform → Mkt Perform
Oct-08-20Downgrade Raymond James Outperform → Mkt Perform
Apr-15-20Resumed Guggenheim Neutral
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-30-20Upgrade Raymond James Mkt Perform → Outperform $255
Mar-05-20Upgrade BofA/Merrill Neutral → Buy $245 → $250
Feb-27-20Initiated Barclays Equal Weight $235
Jan-31-20Downgrade Robert W. Baird Neutral → Underperform $173 → $185
Jan-21-20Upgrade Evercore ISI In-line → Outperform
Jan-25-22 03:01PM  
09:38AM  
09:38AM  
Jan-24-22 05:38PM  
09:49AM  
09:38AM  
09:38AM  
Jan-21-22 06:00PM  
06:00PM  
05:38PM  
01:11PM  
09:18AM  
Jan-20-22 06:15PM  
01:38PM  
11:53AM  
10:41AM  
09:38AM  
09:38AM  
08:52AM  
04:30AM  
Jan-19-22 05:38PM  
05:38PM  
05:38PM  
05:38PM  
01:38PM  
01:38PM  
01:38PM  
09:38AM  
09:38AM  
Jan-18-22 05:38PM  
05:38PM  
01:38PM  
01:38PM  
09:38AM  
Jan-14-22 06:00PM  
02:18PM  
09:38AM  
08:27AM  
Jan-13-22 01:38PM  
10:30AM  
09:33AM  
07:00AM  
Jan-12-22 05:38PM  
10:13AM  
Jan-11-22 02:04PM  
12:10PM  
09:00AM  
Jan-10-22 06:15PM  
05:38PM  
04:00PM  
01:38PM  
10:19AM  
10:07AM  
06:20AM  
12:00AM  
Jan-09-22 02:00PM  
Jan-08-22 09:28AM  
Jan-07-22 01:38PM  
10:24AM  
Jan-06-22 04:00PM  
02:08PM  
09:29AM  
09:00AM  
07:56AM  
Jan-05-22 01:04PM  
11:27AM  
09:38AM  
07:49AM  
06:57AM  
Jan-04-22 06:00PM  
Jan-03-22 06:15PM  
Jan-01-22 10:30AM  
Dec-31-21 06:20AM  
Dec-30-21 08:34AM  
Dec-28-21 06:00PM  
08:14AM  
02:38AM  
Dec-27-21 10:04AM  
Dec-23-21 04:00PM  
Dec-22-21 11:19AM  
Dec-21-21 04:03PM  
09:05AM  
Dec-20-21 05:50PM  
04:25PM  
10:53AM  
05:38AM  
05:19AM  
Dec-17-21 05:08PM  
04:30PM  
09:36AM  
05:09AM  
Dec-16-21 05:21PM  
Dec-15-21 11:15AM  
Dec-14-21 08:38PM  
05:50PM  
03:17PM  
02:41PM  
07:22AM  
Dec-13-21 04:38PM  
12:03PM  
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorMay 12Option Exercise71.641,00071,64016,927May 12 08:11 PM
SUGAR RONALD DDirectorMay 12Sale250.591,000250,59015,927May 12 08:11 PM
Grygiel Nancy A.SVP & CCOMay 11Option Exercise162.602,500406,50014,961May 12 08:10 PM
Grygiel Nancy A.SVP & CCOMay 11Sale252.512,500631,27212,461May 12 08:10 PM
Williams R SandersDirectorMay 07Sale251.7825062,9454,409May 10 06:38 PM
SUGAR RONALD DDirectorApr 14Option Exercise71.641,00071,64016,927Apr 15 06:27 PM
SUGAR RONALD DDirectorApr 14Sale249.981,000249,98015,927Apr 15 06:27 PM
SUGAR RONALD DDirectorMar 10Option Exercise71.641,00071,64016,805Mar 10 06:07 PM
SUGAR RONALD DDirectorMar 10Sale231.531,000231,53015,805Mar 10 06:07 PM
Bradway Robert AChairman, CEO and PresidentFeb 18Option Exercise54.6973,5004,019,715618,380Feb 22 07:27 PM
REESE DAVID MEVP, Research and DevelopmentFeb 16Option Exercise54.692,300125,78742,059Feb 16 08:59 PM
SUGAR RONALD DDirectorFeb 10Option Exercise71.641,00071,64016,805Feb 10 07:40 PM
SUGAR RONALD DDirectorFeb 10Sale238.401,000238,40015,805Feb 10 07:40 PM
Williams R SandersDirectorFeb 08Sale237.9925059,4984,659Feb 08 08:36 PM
Graham Jonathan PEVP, Gen. Counsel & Secy.Feb 04Sale236.5111,1102,627,62539,945Feb 05 08:06 PM